Idarubicin

Therapeutic Group

Anti-neoplastics

Indication Dosage

Indarubicin is indicated for the treatment of various types of cancers, including acute myeloid leukemia (AML) in adults. It is typically used in combination with other chemotherapy drugs as part of a treatment regimen prescribed by a healthcare professional.

Acute Non-lymphocytic Leukaemias Monotherapy: 

By IV Induction: 

  • Adult: 12 Mg/m2/day For 3 Days; Consolidation: 10-12 Mg/m2/day For 2 Days. 
  • Children: 10-12 Mg/m2 Every Day For 3 Day Every 3 Week. 

Acute Non-lymphocytic Leukaemia In Combination Therapy: 

  • Adult: 10-12 Mg/m2 Daily For 3 Days 

Advanced Breast Cancer After Failure Of First-line chemotherapy (not Including Anthracyclines); Monotherapy: 

  • Adult: 15 Mg/m2 Daily For3 Consecutive Days, Repeat Treatment Every 3-4 Weeks; Maximum 400 Mg/m2 Per Course 

Acute Leukaemias, Advanced Breast Cancer After Failure Of First-line Chemotherapy (not Including Anthracyclines): 

  • (Consult Product Literature)

Content

  • Inj: 5mg /10mg: Idarubicin 5mg /10mg; Powder In Vial.

Pregnancy

Positive Evidence Of Risk: Avoid

Stability

  • Cytotoxic Anthracycline Antibiotic

Contra Indications

  • Previous Treatment With Maximum Cumulative Dose Of Idarubicin Or Other Anthracycline, Recent Myocardial Infarction, Severe Arrhythmias, Severe Myocardial Insufficiency

Precautions

  • Previous Treatment With Maximum Cumulative Dose Of Idarubicin Or Other Anthracycline, Recent Myocardial Infarction, Severe Arrhythmias, Severe Myocardial Insufficiency

Lactation

  • Contraindicated. Discontinue Breast-feeding

Side Effects

  • Abdominal Pain
  • Cardiacdisorders
  • Diarrhoea
  • Haemorrhage
  • Rash
  • Red Pigmentation Of The Urine
  • Nail & Skin Hyperpigmentation
  • Alopecia
  • Bone-marrow Suppression
  • Hyperuricaemia
  • Nausea
  • Oral Mucositis
  • Thromboembolism
  • Tumourlysis Syndrome
  • Vomiting
  • Extravasation

Available Brands